This clinical trial is focused on studying a type of cancer known as non-metastatic pancreatic ductal adenocarcinoma. The trial will use a new imaging method involving a special substance called 68Ga-FAPI-46, which is given through an intravenous infusion. This substance is a radiotracer, which means it helps to create detailed images of the body using a technique called Positron Emission Tomography (PET). The purpose of the study is to explore how these images can be used to understand the patient’s condition better and predict their future health outcomes.

Participants in the study will undergo repeated PET-CT scans, which combine PET imaging with computed tomography (CT) to provide a comprehensive view of the cancer. These scans will be done at the start of the study and at various points during the trial. The study aims to see if the images can help identify specific markers that indicate how the cancer might progress or respond to treatment. This could potentially lead to earlier and more accurate diagnosis and monitoring of pancreatic cancer.

The trial will track the time from diagnosis to any changes in the disease, such as progression or recurrence, as well as the time from surgery to any return of the disease. These outcomes will be assessed using routine CT scans, which are typically done every three months, although additional scans may be performed if needed. The study will continue until 2027, with the goal of improving the understanding and management of pancreatic cancer through advanced imaging techniques.